Patent · US Active

Terminally modified RNA

US10155029B2 · kind B2 · utility

10Cited by

2References

15Claims

0Family size

Assignee

ModernaTX, Inc. · US

Inventors

Tirtha Chakraborty · Medford, US
Stephane Bancel · Cambridge, US
Stephen Hoge · Brookline, US
Atanu Roy · Stoneham, US
Antonin de Fougerolles · Waterloo, BE
Noubar B. Afeyan · Lexington, US

Key dates

Filing date	Feb 10, 2017
Grant date	Dec 18, 2018
Priority date	—
Expiry date	Feb 10, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N15/67
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.